|
Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes
|
Apr 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy
|
Oct 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria
|
Aug 2023
|
Haematologica
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Pilot trial of risk-adapted cyclophosphamide intensity based conditioning and HLA matched sibling and unrelated cord blood stem cell transplantation in newly diagnosed pediatric and adolescent recipients with acquired severe aplastic anemia
|
Feb 2014
|
Pediatr Blood Cancer
|
aplastic anemia
|
|
Pitfalls in Assessing Response to Treatment in MDS
|
Sep 2020
|
Clinical Lymphoma , Myeloma & Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes
|
Sep 2014
|
Mod Pathol
|
myelodysplastic syndromes (MDS)
|
|
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS
|
Jul 2014
|
Br J Haematol
|
myelodysplastic syndromes (MDS)
|
|
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes
|
Jul 2023
|
European Journal of Haematology
|
myelodysplastic syndromes (MDS)
|
|
PNH and complement gene variants
|
Apr 2023
|
Blood
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
PNH Phenotypes and Their Genesis
|
Jun 2020
|
British Journal of Haematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
